Literature DB >> 19193873

Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model.

Tie-Shan Tang1, Caixia Guo, Hongyu Wang, Xi Chen, Ilya Bezprozvanny.   

Abstract

Huntington's disease (HD) is a dominantly inherited, progressive neurodegenerative disease caused by an expanded polyglutamine tract in huntingtin protein (Htt). Medium spiny striatal neurons (MSNs) are primarily affected in HD. Mutant huntingtin protein (Htt(exp)) specifically binds to and activates type 1 inositol 1,4,5-trisphosphate receptor (InsP(3)R1), an intracellular Ca(2+) release channel. Htt(exp)-InsP(3)R1 association is mediated by a cytosolic C-terminal tail of InsP(3)R1 (a 122-aa-long IC10 fragment). To evaluate an importance of Htt(exp) association with InsP(3)R1 for HD pathology, we generated lentiviral and adeno-associated viruses expressing GFP-IC10 fusion protein and performed a series of experiments with YAC128 HD transgenic mouse. Infection with Lenti-GFP-IC10 virus stabilized Ca(2+) signaling in cultured YAC128 MSNs and protected YAC128 MSNs from glutamate-induced apoptosis. Intrastriatal injections of AAV1-GFP-IC10 significantly alleviated motor deficits and reduced MSN loss and shrinkage in YAC128 mice. Our results demonstrate an importance of InsP(3)R1-Htt(exp) association for HD pathogenesis and suggested that InsP(3)R1 is a potential therapeutic target for HD. Our data also support potential use of IC10 peptide as a novel HD therapeutic agent.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19193873      PMCID: PMC2768402          DOI: 10.1523/JNEUROSCI.4411-08.2009

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  31 in total

1.  Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice.

Authors:  Xiaofeng Gu; Chenjian Li; Weizheng Wei; Victor Lo; Shiaoching Gong; Shi-Hua Li; Takuji Iwasato; Shigeyoshi Itohara; Xiao-Jiang Li; Istvan Mody; Nathaniel Heintz; X William Yang
Journal:  Neuron       Date:  2005-05-05       Impact factor: 17.173

2.  Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease.

Authors:  R L Albin; A B Young; J B Penney; B Handelin; R Balfour; K D Anderson; D S Markel; W W Tourtellotte; A Reiner
Journal:  N Engl J Med       Date:  1990-05-03       Impact factor: 91.245

3.  Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease.

Authors:  Mannie M Y Fan; Herman B Fernandes; Lily Y J Zhang; Michael R Hayden; Lynn A Raymond
Journal:  J Neurosci       Date:  2007-04-04       Impact factor: 6.167

4.  RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.

Authors:  Scott Q Harper; Patrick D Staber; Xiaohua He; Steven L Eliason; Inês H Martins; Qinwen Mao; Linda Yang; Robert M Kotin; Henry L Paulson; Beverly L Davidson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-05       Impact factor: 11.205

Review 5.  Neuronal calcium signaling.

Authors:  M J Berridge
Journal:  Neuron       Date:  1998-07       Impact factor: 17.173

6.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

Authors: 
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

7.  Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1.

Authors:  Tie-Shan Tang; Huiping Tu; Edmond Y W Chan; Anton Maximov; Zhengnan Wang; Cheryl L Wellington; Michael R Hayden; Ilya Bezprozvanny
Journal:  Neuron       Date:  2003-07-17       Impact factor: 17.173

8.  Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease.

Authors:  R L Albin; A Reiner; K D Anderson; L S Dure; B Handelin; R Balfour; W O Whetsell; J B Penney; A B Young
Journal:  Ann Neurol       Date:  1992-04       Impact factor: 10.422

9.  Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease.

Authors:  Elizabeth J Slow; Jeremy van Raamsdonk; Daniel Rogers; Sarah H Coleman; Rona K Graham; Yu Deng; Rosemary Oh; Nagat Bissada; Sazzad M Hossain; Yu-Zhou Yang; Xiao-Jiang Li; Elizabeth M Simpson; Claire-Anne Gutekunst; Blair R Leavitt; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2003-07-01       Impact factor: 6.150

10.  Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease.

Authors:  Xiaofeng Gu; Véronique M André; Carlos Cepeda; Shi-Hua Li; Xiao-Jiang Li; Michael S Levine; X William Yang
Journal:  Mol Neurodegener       Date:  2007-04-30       Impact factor: 14.195

View more
  46 in total

1.  Expanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of Huntington's disease.

Authors:  Xuesong Chen; Jun Wu; Yuan Luo; Xia Liang; Charlene Supnet; Mee Whi Kim; Gregor P Lotz; Guocheng Yang; Paul J Muchowski; Thomas Kodadek; Ilya Bezprozvanny
Journal:  Chem Biol       Date:  2011-09-23

2.  Role of presenilins in neuronal calcium homeostasis.

Authors:  Hua Zhang; Suya Sun; An Herreman; Bart De Strooper; Ilya Bezprozvanny
Journal:  J Neurosci       Date:  2010-06-23       Impact factor: 6.167

3.  The type III inositol 1,4,5-trisphosphate receptor is associated with aggressiveness of colorectal carcinoma.

Authors:  Kazunori Shibao; Michael J Fiedler; Jun Nagata; Noritaka Minagawa; Keiji Hirata; Yoshifumi Nakayama; Yasuko Iwakiri; Michael H Nathanson; Koji Yamaguchi
Journal:  Cell Calcium       Date:  2010-11-13       Impact factor: 6.817

4.  Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.

Authors:  Ying Dai; Nichole L Dudek; Qian Li; Stephen C Fowler; Nancy A Muma
Journal:  J Neurosci       Date:  2009-09-16       Impact factor: 6.167

Review 5.  The role for alterations in neuronal activity in the pathogenesis of polyglutamine repeat disorders.

Authors:  Ravi Chopra; Vikram G Shakkottai
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

6.  The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease.

Authors:  Daniel Ryskamp; Jun Wu; Michal Geva; Rebecca Kusko; Iris Grossman; Michael Hayden; Ilya Bezprozvanny
Journal:  Neurobiol Dis       Date:  2016-11-03       Impact factor: 5.996

7.  Calcium signaling and neurodegenerative diseases.

Authors:  Ilya Bezprozvanny
Journal:  Trends Mol Med       Date:  2009-02-21       Impact factor: 11.951

8.  Aβ42-binding peptoids as amyloid aggregation inhibitors and detection ligands.

Authors:  Yuan Luo; Sheetal Vali; Suya Sun; Xuesong Chen; Xia Liang; Tatiana Drozhzhina; Elena Popugaeva; Ilya Bezprozvanny
Journal:  ACS Chem Neurosci       Date:  2013-03-07       Impact factor: 4.418

Review 9.  Control of intracellular calcium signaling as a neuroprotective strategy.

Authors:  R Scott Duncan; Daryl L Goad; Michael A Grillo; Simon Kaja; Andrew J Payne; Peter Koulen
Journal:  Molecules       Date:  2010-03-03       Impact factor: 4.411

10.  Tetrabenazine is neuroprotective in Huntington's disease mice.

Authors:  Hongyu Wang; Xi Chen; Yuemei Li; Tie-Shan Tang; Ilya Bezprozvanny
Journal:  Mol Neurodegener       Date:  2010-04-26       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.